double-digit growth emerg market led growth
maintain buy rate upgrad tp
deriv tp base forward price-to-earnings multipl
adjust ep provid upsid potenti
estim top-lin
revenu grow
medtron revenu increas
guidanc revenu
increas adjust
neg impact foreign currenc
net incom
gaap ep non-gaap
ep expect
mn except ep
oper profit increas compar
decreas
compar
cvg revenu increas
decreas due increas
aortic peripher vascular diseas manag decreas
cardiac rhythm heart failur coronari structur
compani name plctickermdtstock ratingbuyunchangedindustri viewoverweightpositivepric aug week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth plc august
incom statement
non-
per share item
product perform develop
valuat consensu perform
mitg revenu decreas
increas due strong
yearli growth respiratori renal solut
rtg revenu grew grew
due strong growth brain therapi
specialti therapi pain therapi
diabet group revenu grew
decreas due growth
announc two-year outcom later
clinic trial evalu use heartwar hvad
systemin patient receiv system via less-
approv ce mark countri
implant via thoracotomi median sternotomi
medtron viz ai emerg leader appli
artifici intellig ai stroke care partner
acceler adopt viz ai new technolog
help synchron stroke care decreas time
treatment potenti improv outcom patient
current price-to-earnings averag price-to-earnings
due increas stock price price-to-earnings show
huge fluctuat last three year due volatil
stock price price-to-earnings trail
expect forward price-to-earnings
expect total revenu increas
neg effect total revenu
expect increas rang
neg impact
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share outstand n/a held held share short short float n/a share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend ex-dividend last split factor new per last split inform plc august
incom statement
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research sale gener restructur amort oper total oper oper interest incom incom provis incom net incom continu net incom avail common earn per weight averag share estim annual actual annual actual quarterli plc august
cash short-term total prepaid current total current net properti plant intang long-term total non-curr total short-term capit account defer incom taxestax accru current total current long-term capit defer tax pension minor long-term total non-curr total addit paid-in retain accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu annual actual quarterli plc august
increas cash oper activ due margin expans well decreas cash paid
vendor tax interest retir benefit plan contribut increas partial off-set
increas certain litig payment decreas cash paid supplier primarili due progress
extend supplier payment term decreas cash tax due pre-pay
 ir relat in-process litig puerto rico transfer price paid interest
decreas due decreas total debt oblig weight averag interest rate outstand debt
decreas retir benefit plan contribut due lower contribut pension plan
increas certain litig payment due payment previous accru settlement
amount infus litig matter
cash use invest activ increas increas due divestitur
worth result net proce increas cash paid acquisit
due acquisit mazor epix increas cash paid partial off-set increas
net proce purchas sale matur invest
use financ activ decreas due issuanc euro-denomin
senior note partial off-set increas share repurchas increas
repay commerci paper
depreci invest loss defer incom stock base chang work account work non-cash net cash provid oper invest properti plant acquisit purchas sales/matur invest net cash use invest debt debt common stock common stock dividend financ net cash provid use financ effect exchang rate net chang begin end free oper cash capit free cash plc august
plc deliv growth compar quarterli
result show flat revenu increas cost
increas
net revenu increas revenu increas
organ basi adjust neg impact
foreign currenc growth revenu due out-performance
mitg rtg strength emerg market offset challeng cvg
difficult comparison diabet
cog increas
compar
total revenu repres compani revenu
increas report non-u develop market revenu
repres compani revenu decreas
report increas constant currenc basi emerg market
revenu repres compani revenu
increas report constant currenc basi
cog increas compar
sg expens increas compar
sg expens sale non-
sg expens
 expens compar
amort intang asset decreas
compar restructur charg
compar
oper incom net compar
oper expens net oper incom
includ relat earli redempt medtron inc
cisfa
compar
oper profit increas compar
oper margin non-gaap oper margin
non-oper incom net compar
interest expens compar
gaap ep
compar
tax rate compar
non-gaap tax rate compar
decreas tax rate due impact tax reform tax
cost associ intern reorgan partial off-set tax
effect inter-company sale intellectu properti impact
divestitur patient care deep vein thrombosi nutrit
net incom decreas compar net
incom non-gaap net incom
gaap ep compar non-gaap
ep compar
compar
year total revenu increas organ basi
compar revenu adjust
divestitur certain busi cardin occur
neg impact foreign currenc
year total revenu increas compar
non-u develop market revenu increas
year compar total
revenu emerg market increas year
compar
cog increas
compar
amort
decreas
compar
cog increas compar cog
decreas net sale compar
decreas due decreas sale lower-margin product result
decreas also due infus set recal diabet group along
cost recogn relat restor oper four puerto
rico manufactur site hurrican maria includ idl facil cost
asset write-down facility-rel cost incur
partial off-set increas restructur associ cost chang
product mix due strong growth lower margin busi
addit expens incur due close supplier steril facil
minim invas therapi group cog includ
restructur associ cost compar
 expens increas compar
 expens net sale remain flat year
compar
sg expens increas compar
sg expens net sale decreas
compar decreas sg expens net
sale benefit enterpris excel program continu net sale
growth cost contain measur profession servic fee
acceler stock compens expens incur connect
divestitur sg expens includ
restructur associ cost compar
amort intang asset declin
compar amort intang asset includ
amort expens definite-liv intang asset consist
technolog intang asset
restructur charg net increas compar
certain litig charg increas
compar oper expens net declin
compar
oper profit compar
non-oper incom net compar
interest expens compar
incom tax rate compar
net incom increas compar
ep compar non-
gaap ep compar
decreas
compar
net incom increas
year
compar
oper four segment cardiac vascular group cvg
rtg diabet group
four princip segment strateg busi manag
separ one develop manufactur product provid
decreas
decreas
cardiac vascular group cvg
cardiac vascular group cvg includ cardiac rhythm heart
failur crhf coronari structur heart csh aortic peripher
cvg fourth quarter revenu decreas report
increas constant currenc basi cvg fourth quarter revenu
perform driven mid-singl digit growth apv csh off-set
low-singl digit declin crhf constant currenc basi
cvg fiscal year revenu increas report
increas constant currenc basi cardiac vascular
group revenu compar benefit revenu
growth coronari structur heart aortic peripher aortic
peripher vascular divis off-set declin cardiac rhythm heart
revenu market increas
compar revenu non-u develop
market decreas compar
revenu emerg market increas
compar
total revenu decreas report
constant currenc basi revenu decreas
compar decreas revenu
due declin heart failur manag servic clm
decreas off-set growth arrhythmia manag declin
heart failur driven crt-d replac lvad headwind
due competitor product launch chang
increas
increas
cardiac vascular group cvg
growth arrhythmia manag driven af solut due
continu strength arctic front cardiac cryoablat cathet
diagnost due growth reveal linq insert cardiac
arrhythmia manag revenu growth also benefit strong
adopt tyrx absorb antibacteri envelop
expans value-bas health care arrang
total revenu decreas report
increas constant currenc basi revenu increas
compar
increas driven global strength corevalu evolut
transcathet aortic system continu penetr intermedi
risk well growth cannula includ bio-medicu
cannula guid cathet coronari balloon
total revenu increas report increas
constant currenc basi revenu increas
increas revenu driven strong
perform venas vein closur system final approv
reimburs payment center medicar
medicaid servic receiv januari
increas also due growth percutan translumin
angioplasti pta balloon well launch valiant navion
thorac stent graft system receiv fda ce mark approv
octob novemb respect
minim invas therapi group mitg includ surgic
innov si respiratori gastrointestin renal divis
minim invas therapi group product span entir continuum
patient care diagnosi recoveri focu diseas
gastrointestin tract lung pelvic region kidney obes prevent
product includ advanc gener surgic product includ
dialysi monitor
mitg fiscal year revenu decreas report
increas compar constant currenc basi mitg fourth quarter
revenu increas report increas
mitg fourth quarter revenu driven balanc growth across
divis mid-singl digit constant currenc growth si
revenu market decreas
compar revenu non-u develop
market decreas compar
revenu emerg market increas
compar
total revenu increas report increas
constant currenc basi revenu increas
year compar
increas
si revenu increas
increas
decreas
increas driven new product advanc stapl advanc
led ligasur vessel seal instrument nano-co
exact l-hook tri-stapl endo stapl specialti reload
signia power stapler
total revenu increas report increas
constant currenc basi revenu decreas
year compar
decreas due declin divestitur respiratori gastrointestin
renal apart declin net sale growth driven growth
patient monitor includ continu adopt microstream
capnographi monitor product puls oximetri along growth
respiratori intervent includ continu adopt ventil
video laryngoscopi product also growth gi
hepatolog strength renal access product
restor therapi group rtg includ brain therapi spine
specialti therapi pain therapi divis product focu variou
area spine bone graft substitut biolog product trauma implant
neurostimul therapi drug deliveri system treatment
retent fecal incontin gastroparesi well product treat
condit ear nose throat system incorpor advanc
increas
decreas
restor therapi group also manufactur sell image-guid
surgeri intra-op imag system robot guidanc system use
robot assist spine procedur therapi treat diseas
vasculatur around brain includ coil neurovascular stent
retriev flow divers product
rtg fiscal year revenu increas report
constant currenc basi rtg fourth quarter revenu increas
report constant currenc basi currenc
neg impact revenu
restor therapi group perform driven brain
therapi specialti therapi pain therapi
revenu market increas
compar revenu non-u develop
market increas compar
revenu emerg market increas
year compar year
fourth quarter revenu decreas report increas
constant currenc basi revenu decreas
recent launch product includ infin oct
solera voyag fixat system
decreas off-set increas increment growth due increas
spinal impact attach rate conjunct surgic synergi strategi
integr spinal implant enabl technolog robot
imag navig power instrument nerv monitor
growth due speed scale initi involv faster innov
cycl launch steadi cadenc new product scale
set immedi avail entir market
fourth quarter revenu increas report
constant currenc basi revenu increas
compar increas due strong
growth neurovascular neurosurgeri
neurovascular revenu growth driven strength across stroke franchis
growth across stent retriev flow divers neuro access coil
embol protect product neurosurgeri revenu growth driven
strong capit equip sale mazor robot guidanc system
instrument system o-arm imag system visualas mri-guid laser
fourth quarter revenu increas report
constant currenc basi revenu increas
increas due strong sale aquamantyss biopolar
sealer plasmablad dissect devic within transform solut
growth ent
fourth quarter revenu increas report
constant currenc basi revenu increas
year compar increas due
intelli spinal cord stimul platform receiv fda approv
septemb ce mark novemb revenu growth
also due evolv workflow algorithm snapshot report target drug
deliveri product includ new clinic patient programm
increas
increas
revenu increas
increas
increas
increas
increas
decreas
monitor cgm system insulin pump consum therapi
diabet group fiscal year revenu increas report
constant currenc basi diabet group fourth
quarter revenu decreas report increas
despit face difficult comparison pump sale given backlog
patient order compani clear prior year revenu increas
versu prior quarter report
diabet group net sale growth attribut continu
demand minim hybrid close loop system offer
latest smartguard technolog well higher sensor attach
util see integr cgm user
experienc continu intern growth due strong sale
insulin pump system europ latin america asia pacif well
world-wide strength guardian connect cgm system
revenu market increas
compar revenu non-u develop
market increas compar
revenu emerg market increas
year compar year
strong mid-teen growth intern market driven
on-going launch minim hybrid close loop insulin pump
system guardian sensor off-set difficult comparison
increas competit
global adopt sensor-aug insulin pump system result
strong sensor attach rate integr cgm sale grow
high-teen constant currenc basi
fourth quarter revenu grew low-sixti constant currenc
basi driven on-going launch guardian connect cgm system
sugar iq person diabet assist grew tripl digit
total revenu expect
increas
increas
non-gaap ep
expect
rang
estim
neg impact
due current rate
total revenu expect organ basi neg effect
non-gaap ep expect rang
estim neg impact due current rate foreign exchang
revenu growth cvg expect grow mitg expect grow
rtg expect grow diabet expect grow
organ basi
estim tax rate increas
total organ revenu growth expect rang
neg impact
revenu growth cvg expect flat mitg rtg expect
grow diabet expect grow organ basi
non-gaap ep expect rang
estim neg impact due currenc headwind recent rate
revenu grew
growth
mitg rtg segment
growth emerg
revenu grew growth mitg
rtg segment growth emerg market total revenu increas
compar market repres
revenu increas non-u market repres
revenu emerg market repres revenu
cog increas cog net sale reduc
compar decreas due
decreas sale lower-margin product decreas infus set recal
diabet group partial off-set increas restructur associ cost
net incom increas compar
mitg revenu decreas increas
mitg fourth quarter revenu driven balanc
growth divis strong perform divis mid-singl
rtg perform driven brain therapi specialti therapi
pain therapi revenu increas
revenu increas revenu brain
therapi increas increas due strong growth
neurovascular neurosurgeri
ytd stock perform current price-to-earnings
averag roa roi roe ttm
basi respect total revenu expect increas organ basi
total revenu expect increas
percent freedom disabl stroke year announc
two-year outcom later clinic trial evalu use
heartwar hvad systemin patient receiv system via less-invas
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
product perform develop
valuat consensu perform
gross margin ttm basi increas compar due
decreas cog
oper margin ttm basi increas compar
due decreas expens
net margin ttm basi increas compar
due decreas tax rate
ep growth ttm basi increas compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth plc august
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale medtron plc august
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset medtron plc august
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item medtron plc august
balanc sheet item
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free plc august
current price-to-earnings averag price-to-earnings due increas stock price price-to-earnings
show huge fluctuat last three year due volatil stock price price-to-earnings highest
septemb price-to-earnings trail
expect forward price-to-earnings
incom statement
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc wellington manag compani massachusett servic lazard asset manag price row associ geod capit manag jp morgan top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard/windsor mf seri trust valu fund vanguard institut fund-institut vanguard/wellington fund vanguard specialized-dividend appreci vanguard specialized-dividend growth fund fidel fund plc august
developmentsmedtron request approv non-adjunct label fdajuli announc pre-market approv pma submiss food drug administr fda request approv non-adjunct label guardian sensor part minim system fda approv sensor non-adjunct label mean sensor accur enough use calcul insulin dose meal correct high glucos level sinc medicar requir non-adjunt label sensor reimburs approv label could broaden patient access allow medicar coverag world first still commerci avail hybrid close loop system medtron partner viz ai acceler adopt new artifici intellig softwar stroke centersjuli viz ai emerg leader appli artifici intellig ai stroke care partner acceler adopt viz ai new technolog help synchronis stroke care decreas time treatment potenti improv outcom patient viz ai technolog use artifici intellig identifi suspect larg vessel occlus lvo stroke automat notifi specialist viz ai softwar connect hospit comput tomographi ct scanner alert stroke specialist within minut suspect lvo stroke identifi send radiolog imag directli smart phone view viz ai enabl physician provid patient treatment need quickli possibl medtron heartwar tm hvad tm implant via less invas thoracotomi show percent freedom disabl stroke yearsjuli announc two-year outcom later clinic trial evalu use heartwar hvad systemin patient receiv system via less-invas thoracotomi implant approach hvad system heart pump call left ventricular assist devic lvad help increas amount blood circul bodi patient advanc heart failur hvad pump world smallest commerci avail full support centrifug lvad full support lvad clinic evid demonstr safeti effect implant via less-invas thoracotomi approach hvad system approv ce mark countri implant via thoracotomi median sternotomi hvad thoracotomi implant involv small later surgic incis rib left side chest insert pump second small incis attach outflow graft tradit median sternotomi approach requir vertic incis middl chest divid sternum medtron plc august
incom statement
non-
per share item
product perform develop
valuat consensu perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit plc august
consensu view analyst trend stock
flat
 average
forward price-to-earnings
compar
mdt avgfive-year growth forecast usdgrowth high day day day estim comparisonmdtindustri avg avgprice/earn yield plc august
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate medtron plc august
incom statement
non-
per share item
product perform develop
valuat consensu perform
stock price shown upward trend rang quarter
stock gave return period averag volum share trade
stock price volatil past dip januari april
stock gave return past rang stock
stock price volatil surg juli
stock gave return past dip decemb
deliv strong perform year growth revenu due strong growth
emerg market new product launch recommend buy rate stock tp
base perform new product launch
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
